



Hole, B., Caskey, F., Roderick, P., & Tonkin-Crine, S. (2016). Treatment of End-stage Kidney Failure without Renal Replacement Therapy. Making Dialysis Adequate – Addressing its Limitations. *Seminars in Dialysis*, 29(6), 491. [10.1111/sdi.12535]. <https://doi.org/10.1111/sdi.12535>

Peer reviewed version

Link to published version (if available):  
[10.1111/sdi.12535](https://doi.org/10.1111/sdi.12535)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Wiley at <http://onlinelibrary.wiley.com/doi/10.1111/sdi.12535/abstract>. Please refer to any applicable terms of use of the publisher.

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: <http://www.bristol.ac.uk/pure/user-guides/explore-bristol-research/ebr-terms/>

## Treatment of End-stage Kidney Failure without Renal Replacement Therapy

Barnaby Hole,\* Sarah Tonkin-Crine,† Fergus J. Caskey,‡ and Paul Roderick§

\*Department of Renal Medicine, North Bristol NHS Trust, Southmead Hospital, Bristol, United Kingdom, †Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom, ‡UK Renal Registry, Learning and Research, Southmead Hospital, Bristol and School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom, and §Academic Unit of Primary Care and Population Sciences, Faculty of Medicine, University of Southampton and the University Hospital Southampton NHS Trust, Southampton, United Kingdom

### ABSTRACT

For the majority of patients with end-stage kidney failure (ESKF) replacement of excretory renal function by dialysis or transplantation (RRT) can extend life and alleviate symptoms. Historically, the availability of RRT has been insufficient and this remains the case for much of the world. However, RRT is now widely available in health-care systems of higher income countries. Increasing numbers of elderly patients are developing ESKF. RRT in this population is largely by dialysis, comorbidity is high and life expectancy short. Evidence of effectiveness coupled with the burden of treatment among these individuals has raised concerns that health services in high-income countries may have moved from an era of unmet need into one of potential over-treatment. Alongside the requirement to make treatment more patient-centered, this has driven the development of comprehensive conservative care as an alternative approach for older comorbid individuals with ESKF, with the potential for acceptable symptom control and reduced treatment burden. This

paper provides a largely UK-perspective on treating ESKF without RRT. Emphasis is on the need for high-quality evidence to inform treatment decisions. Complexities of defining, delivering and improving treatment of ESKF without dialysis care are explored. Quantitative and qualitative evidence are summarized and the relationship with palliative and terminal care examined. A framework is suggested for classifying management of ESKF and recommendations made to improve delivery of nondialysis care in the future. For patients with a poor prognosis, such treatment may not result in significantly different survival or quality of life when compared with dialysis. There is a key need to generate the best possible evidence of person-centered health outcomes associated with the various treatment options for ESKF and to present this to patients in a balanced, personalized way that allows them to make the treatment decision most appropriate for them.

Renal replacement therapy (RRT) using dialysis has been available for the treatment of end-stage kidney failure (ESKF) from the 1960s. Early technology and availability meant it was offered only to those with the best prognosis. Infamously, this led to the development of committees responsible for directing limited capacity toward those felt most 'eligible' (1). RRT remains an expensive therapy largely unavailable to the populations of lower income countries (2,3). In higher income countries, successive health policy changes have seen progressive

service expansion, and capacity no longer restricts dialysis provision. Improvement in outcomes from long-term dialysis allows patients with ESKF to live longer (4). Despite a plateauing of RRT incidence in many countries, the prevalent population receiving dialysis continues to expand (5). Compounded by the limited supply of transplant organs, the population with ESKF has shifted from largely working-age people with single organ disease to one increasingly comprising older, more comorbid individuals, predominantly receiving in-center hemodialysis (6). With the United Kingdom general population aged over 65 predicted to increase by 60%, from 10.3 to 16.9 million by 2035 this trend seems set to continue (7).

As people live longer and die with chronic, non-communicable disease, cultural attitudes toward illness, treatment and death have changed (8). Illness and dying are perceived as preventable, even in an

*Address correspondence to:* Professor Paul Roderick MD, Academic Unit of Primary Care and Population Sciences, Faculty of Medicine, University of Southampton, University Hospital Southampton NHS Trust, Tremona Road, Southampton SO166YD, UK, e-mail: pjr@soton.ac.uk.

*Seminars in Dialysis*—2016

DOI: 10.1111/sdi.12535

© 2016 Wiley Periodicals, Inc.

individual's older and last years. In the United Kingdom, almost half of adults die in a hospital bed (9) and about one in five Americans die during a hospitalization including intensive care (10). Patients approaching the end of life are frequently in receipt of polypharmacy (11). Revolutionary advances in medicine have been replaced by gradual refinement of practice and development of increasingly expensive, higher technology treatments with slighter, incremental benefits to the individual. In parallel, there has been a practice shift away from paternalistic medicine toward increasingly holistic and patient-centered care. Shared decision-making empowers individuals and their carers to make choices about what care they want based on honest, open disclosure of the known benefits and risks of proposed treatment options (12). The model of 'cumulative complexity' recognizes a requirement for individuals to cope with demands of illness and treatment, and that incapacity to cope with these demands can lead to further negative health outcomes (13). So called 'minimally disruptive medicine' advocates a pragmatic approach to therapeutic recommendations in an effort to minimize treatment burden on patients and their carers, especially those with major comorbidity or approaching the end of life (14).

Preparation for RRT involves planning for in-center hemodialysis for most older comorbid patients with advanced chronic kidney disease (CKD) and guidelines promote education and vascular access well in advance of ESKF (15–17). The benefits of this approach are available only to those who survive to start RRT, whereas every patient is exposed to the burdens and associated risk of harm of preparing for dialysis. Some individuals elect for the symptoms and complications of their kidney disease to be managed without RRT. Terminology for this approach includes 'comprehensive conservative care' (CCC—used in this paper) (18), 'nondialysis care' and 'conservative kidney management' (19,20). The comparative effectiveness of dialysis and CCC has been studied in countries which have formally introduced such pathways and is discussed in more detail below.

Historically, the UK RRT program has had lower uptake than many other countries with comparable populations, although rates have increased (21). It is not easy to disentangle the role of rationing (implicit or explicit) in this, as compared with careful and appropriate use of treatment. Nevertheless, CCC is more accepted in the United Kingdom than in many other developed countries, affording a key perspective from which to examine the evidence base for its appropriate and effective development. In this paper, the complexities surrounding definition and identification of ESKF are examined. Pathways of CKD care are illustrated and a treatment classification advanced. Quantitative and qualitative evidence of outcomes and experiences of CCC and dialysis are summarized. Approaches to the development of higher quality evidence to

support clinicians and patients in making better-informed decisions about how to plan for ESKF are proposed.

### Incidence and Prevalence of ESKF

Robust, population-based data to describe ESKF epidemiology are unavailable (Fig. 1). RRT registries only systematically collect individual patient outcomes and describe the natural history of RRT-treated ESKF. RRT receipt is influenced by levels of detection of advanced CKD, referral and acceptance on to RRT. Internationally, RRT treatment has been increasing steadily over the last few decades, although rates in higher income countries have stabilized more recently (5). While this increase is substantially due to population ageing, rising prevalence of diabetes and decline in competing mortality risk from cardiovascular disease, it also reflects expansion in dialysis services and changing referral and acceptance rates, highlighting the inadequacy of studying ESKF epidemiology using RRT receipt. Hospitalization data are an invalid measure of ESKF incidence or prevalence because they relate only to known treated inpatient cases and lack clarity due to insufficiencies in International Classification of Diseases coding. Beyond reach of routinely captured data are those with undiagnosed ESKF who have never had blood tests. Mortality data are unreliable because of under-ascertainment of renal disease on death certificates (22). Cohort studies suggest the incidence of CKD has been relatively stable in comparison with growth in RRT-treated ESKF (23), but CKD registries are not widespread.

RRT treatment in the United Kingdom has been rising fastest among those aged over 75 years, who now account for almost a quarter of new dialysis patients (21). Comorbidity is prevalent and increases with age (6). Of patients aged over 65 commencing dialysis, 82% receive hemodialysis (21) and transplantation is not an option for most, especially once aged over 75 (24). Fifty-five percent of 65–74 year olds and 40% of those aged 75 or over survive 3 years. However, 30% of over-85 year olds die within 1 year of commencing dialysis (4). Early mortality is probably underestimated due to incomplete registry data for patients receiving dialysis following acute decompensation (25) (Fig. 1). In the United Kingdom, 19% of deaths within 1 year of commencing dialysis among patients aged over 65 are due to withdrawal from treatment and rates are rising (4).

For much of the globe, there remains a deficiency of organized data on the incidence and prevalence of ESKF, provision for its treatment and its outcomes (26). Considerable portions of the world population have no access to specialist renal services. Once ESKF develops individuals are likely to either remain undiagnosed, or be diagnosed and unable to access RRT. Reported global incidence rates for




FIG. 1. Pathway for people with advanced chronic kidney disease in primary or secondary care with reference to potential data sources on numbers affected and outcomes. Black/gray shaded boxes represent areas where no/limited data exist. CKD chronic kidney disease, CCC comprehensive conservative care, RRT renal replacement therapy.

RRT-treated ESKF range from 12 to 455 (median 130) per million population (3). This variation reflects factors including population health and demography including disease burden. However, macroeconomic and service factors such as Gross Domestic Product spent per capita, percentage of Gross Domestic Product spent on health care, dialysis reimbursement rate and the private for profit share of dialysis provision are more strongly associated (3). Work needs to be done to join up these various sources of data on CKD in different settings and gain a full picture of the care of people with CKD and ESKF, though the solutions are likely to have to be specific to the databases and information governance laws in the different countries.

### Provision of Nondialysis Care

While CCC is recognized and delivered widely (19,20,27–29), the international population of individuals receiving CCC has not been evaluated. Scope and practice patterns of CCC in the United Kingdom have been systematically recorded (20). A nondialysis pathway was available in nearly every UK renal unit. Data on the number of older patients on a nondialysis pathway were available for almost half of units, and varied greatly from 4 to 152, often but not always reflecting the total population of patients in a unit. Data on symptomatic older patients on a nondialysis pathway, perhaps a

better gauge of CCC delivery, also varied widely, ranging from 1 to 50 patients per unit. Approximately one in five units had clinics exclusively for patients on a nondialysis pathway and this was closely related to whether they had staff primarily responsible, and funding, for nondialysis care. Unlike RRT preparation and delivery, CCC receives no automatic payment by results within UK health-care tariffs. Linkage with primary care data was available for a small number of units and suggested that most (94%) individuals with CKD stage 5 were known to renal services. What degree of triage occurred before laboratory testing in primary care was not examined.

The very wide variation in numbers of patients receiving nondialysis care (20) is likely to reflect, in part, the lack of an agreed definition of the pathway and highlights the need for a uniform terminology (19). Variation also reflects local CKD identification, referral and treatment patterns along with deviation in population demographics. The trend over the past decade has been for increasing investment in such services (30) and some units have shown considerable investment in staff time and dedicated processes to support patients on a nondialysis pathway.

In 2013, Kidney Disease: Improving Global Outcomes (KDIGO), in partnership with the International Society of Nephrology (ISN), held a conference to develop consensus on the application of palliative care in CKD (18). The lack of clear

definitions was felt to have constrained both treatment and research for this population. A definition of CCC was proposed including all aspects of care for individuals with ESKF managed without RRT (Table 1). The conference represented a milestone in the care of patients with or approaching ESKF and prepared the ground for development of an evidence base from which care and outcomes can be improved.

### Treatment of Individuals with or Approaching ESKF: A Proposed Terminology

An agreed terminology for treatment of those with or approaching ESKF is necessary to facilitate communication with patients, carers, clinicians and policy makers. In research and policy, evidence, guidance and direction can be developed only once patient populations are defined. The KDIGO/ISN conference defined supportive care and CCC, but did not produce a classification of treatment pathways where both RRT and CCC are available (18). A classification is proposed in Fig. 2.

The proposed classification uses 'ESKF' to describe sufficiently impaired kidney function such that individuals are in receipt of either RRT or CCC (after a putative point similar to an indication to start RRT). Estimated glomerular filtration rate (eGFR) associates imperfectly with disease severity and cannot alone identify ESKF (31). Serum creatinine reflects body composition as well as renal function and loses precision as a marker of kidney function in individuals with low muscle mass, malnourishment, or at extremes of age (32). Some individuals with an eGFR as high as  $\geq 15$  ml/minute/1.73 m<sup>2</sup> have substantial symptoms or biochemical complications and a small number initiate dialysis at this stage (33). Many patients with eGFR < 15 ml/minute/1.73 m<sup>2</sup> have acceptable fluid balance, biochemistry and symptom control and stability of kidney function.

Initiation of dialysis is not an unambiguous marker of ESKF. Initiating dialysis preemptively does not provide benefit over waiting for an indication to

commence treatment (34). Symptoms, hyperkalemia and fluid overload increase with declining kidney function, but are not categorical phenomena—the risk of sudden death, for example, increases progressively with rising serum potassium concentration (35). Individuals (36) and their clinicians (37) weigh potential benefits and burdens of treatment differently depending on personal preferences and values and despite similar disease profiles, may initiate dialysis—thus acquiring a label of treated ESKF—at different times. Some will consider the benefits of dialysis insufficient to outweigh the burdens and choose nondialysis care (36). The point at which such individuals have progressed from nondialysis preparation to CCC may be difficult to identify with precision. The proposed classification recognizes the difference between individuals who are not planning for RRT if ESKF develops and others receiving CCC who would be undergoing dialysis if that had been the chosen mode of care. However, the dividing lines are indistinct, reflecting gradual progression of disease, plasticity of decision-making and the elusiveness of a definition for ESKF.

Decision-making is a process, not an epiphany and this is reflected by the ability for patients to move freely between the pathways, both at preparatory and ESKF phases. Individuals presenting late to renal services (Fig. 1) may develop ESKF without being on either pathway and need to elect for RRT or CCC at short notice.

Access to supportive care, advance planning and palliative services should not be influenced by which pathway a patient has chosen. As comorbidities develop and an end of life phase approaches, care may become progressively palliative on either pathway and some patients receiving RRT may choose to withdraw from dialysis. A greater proportion of patients opting for CCC may already be at this stage, but supportive care is a component of both pathways as depicted in Fig. 2.

### Comparing Outcomes between RRT and Nondialysis Care

Tables 2 and 3 summarize key studies that have compared the outcomes of patients receiving nondialysis and RRT care. All have been observational in design, and with only three prospective cohorts (29,38,39). Most have been single center and from the United Kingdom, including three from the same unit (38,40,41). The cohorts are small, with only four including over 100 patients on a nondialysis pathway. In total, 913 patients receiving nondialysis care were included. There are methodological issues with the comparisons which include: dealing with selection bias in allocation (treatment by indication) and residual confounding; identification of a start time for survival analysis with long lead times in advanced CKD (and potential for lead time bias); exclusion criteria; uncertain disease progression and prognosis in individuals

**TABLE 1. Definition of comprehensive conservative care (CCC) following the KDIGO Controversies Conference on supportive care in chronic kidney disease (18)**

CCC is planned holistic patient-centered care for patients with CKD stage five including the following

- Interventions to delay progression of kidney disease and minimize adverse events or complications
- Shared decision-making
- Active symptom management
- Detailed communication including advance care planning
- Psychological support
- Social and family support
- Cultural and spiritual domains of care

CCC care does not include dialysis.  
CKD, chronic kidney disease.




FIG. 2. Proposed classification of treatment of patients with or approaching ESKF. Left: conceptual framework from the KDIGO Controversies Conference on Supportive Care in Chronic Kidney Disease(18). Right: RRT (upper) and nondialysis (lower) preparation pathways. Individuals with advanced CKD who anticipate commencing RRT if/when ESKF develops are classified as receiving ‘RRT preparation’. Those who opt not to prepare for RRT are classified as receiving ‘nondialysis preparation’. In some, symptoms or biochemical abnormalities trigger RRT initiation (A). From this point, such individuals are classified as having ESKF and receiving RRT. At an equivalent point (B), patients who choose not to commence RRT should be classified as having ESKF and receiving CCC, although identifying this ‘putative dialysis’ point in practice is difficult (see text). Many patients will die before ESKF develops (C). Patients can move freely between the pathways, during both preparatory and ESKF phases (double arrows). All patients are eligible for supportive care as defined by the KDIGO guideline, though supportive needs may be greater among the nondialysis group (curved areas). CKD, chronic kidney disease; RRT, renal replacement therapy; CCC, comprehensive conservative care; ESKF, end-stage kidney failure.

approaching ESKF; and variation in threshold for RRT initiation between individuals, units and countries; cross-over between pathways and failure of intention to treat analysis, and limited outcome data.

Patients on a nondialysis pathway tended to be older, more comorbid and have poorer functional status (38,41–43), although this was not found in all studies (39). Selection bias was addressed by restriction or multivariate analysis including propensity scoring (see Table 3). However, residual confounding was a problem given the limited set of routinely available variables in retrospective studies from which adjustments can be made. There was typically no adjustment made for functional status, frailty, malnutrition, or cognitive impairment.

Identifying equivalent time points for individuals on RRT and nondialysis pathways is necessary for survival comparisons. Approaches to start time allocation have included time of recording of decision-making (intention to treat), estimating a putative eGFR indicating ESKF and its timing in those on a nondialysis pathway, and time of reaching a threshold eGFR (see Table 2). Time of decision-making fails to distinguish patients in a preparatory phase from those in receipt of CCC and treatment

decisions may be made at different times among those who choose RRT and nondialysis pathways. Most studies excluded individuals first presenting to renal services with an eGFR <10–15 ml/min/1.73 m<sup>2</sup> on the grounds there was little time for decision-making and high use of RRT in this group. Such patients are often older and more comorbid and are likely to have poor outcomes. The limitations of eGFR as a marker of ESKF have already been outlined. Outcome data available were largely restricted to survival, with a lack of cause of death statistics to inform the role of direct death from ESKF in those treated with CCC. Only three studies investigated quality of life (29,38,39).

Compared with patients of the same age receiving dialysis, there was a survival disadvantage associated with nondialysis care, but this diminished and even disappeared when comparison was restricted to patients with high comorbidity or on multivariate analysis (40,43–46), though this was not found in all studies (38,47). Patients receiving nondialysis care were more likely to die out of hospital, with palliative care input, and less likely to have an ‘over-medicalised’ death (41,43,45,48). The patients receiving RRT, who were largely treated with in-center hemodialysis, had greater

TABLE 2. Characteristics of studies comparing comprehensive conservative care (CCC) and dialysis

Study	Setting	Design	Conservative care intervention	Primary outcome	Sample characteristics		Baseline comparison CCC vs. RRT
					CCC	Dialysis	
July, 2003 (42)	France Single center	Retrospective cohort Consecutive referrals Age >80 Creatinine Clearance <10 1989–2000	Palliative care Fluid balance Symptom control Psychological social and spiritual care	Mortality Time 0 = at day started RRT or date decision not to perform dialysis recorded	N = 37 Mean age 84	N = 107 Mean age 83 HD 6 patients switched to CCC	+Comorbidity +Social isolation, +Late referral, +Diabetes –Karnofsky score
Smith, 2003 (41)	UK Single center (Lister)	Retrospective cohort All referrals 1996–2000	Ongoing support by multidisciplinary team in liaison with community and hospice, and full medical care	Mortality Time = 0 at putative dialysis initiation Mean eGFR 9.4 ml/minute	N = 63 Mean age 71 10 CCC patients switched to RRT	N = 258 Mean age 59 Six patients declined RRT	+Age +Comorbidity –Karnofsky score
Murtagh, 2007 (44)	UK Four centers	Retrospective cohort pre-dialysis care clinic referrals age >75 (excluded late presenters, first presentation eGFR<15, terminal malignancy) 2003–2004	Dedicated multidisciplinary care	Mortality Time = 0 at first date eGFR<15	N = 77 Mean age 83	N = 52 Mean age 80	+Age No other differences No functional measures
Carson, 2009 (48)	UK Single center	Retrospective cohort Age ≥70, Started RRT or CCC Included late referrals 1997–2003	Clinic follow-up Optimized hemoglobin and blood pressure plan same in both groups. In CCC calcium and phosphate control. Diuretic treatment. Dietary restriction only for potassium.	Mortality Time = 0 at start RRT and putative dialysis initiation date in CCC (threshold eGFR in RRT group = first eGFR <10.8 ml/minute)	N = 29 Mean age 82	N = 173 Mean age 76 All modes	+Age
Teo, 2010 (47)	Singapore Single center	Retrospective cohort of new ESKD (not defined) 2005	Not reported	Mortality and hospitalization Time = 0 at ESKF diagnosis Treatment mode defined at 90 days after time = 0	N = 16 Mean age 67	N = 152 Mean age 59 All modes	

Table 2. (Continued)

Study	Setting	Design	Conservative care intervention	Primary outcome	Sample characteristics		Baseline comparison CCC vs. RRT
					CCC	Dialysis	
Chandna, 2011 (40)	UK Single center (Lister)	Retrospective cohort eGFR <15 (excluded those presenting <10) 1990–2008	Multidisciplinary team liaising with community primary care and hospice services	Mortality Time = 0 at first eGFR <15	N = 155 Age at CKD5 Mean 78	N = 689 Age at CKD5 Mean 59 All modes	+Age +Comorbidity
Da Silva-Gane, 2012 (38)	UK Single center (Lister)	Prospective cohort Advanced CKD 70% response rate Serial Quality of life assessments Decisions on mode up to 15 months after 16 patients remained Undecided 2005–06	Medical treatment and multidisciplinary Support	Mortality Time = 0 at date enrolled in study (eGFR approximately 13) Used propensity scoring and multilevel models for quality of life over time	N = 30 Mean age 78	N = 124 Mean age 61 All modes	+Age +Comorbidity +HADS anxiety – Karnofsky – SF36 PCS
Hussain, 2013 (43)	UK Single center	Retrospective cohort Age ≥70 eGFR <20 Excluded late referrals presenting eGFR <15 2006–11	Multidisciplinary review Palliative medicine consultant review and care led by them for those with symptomatic uraemia Emphasis on symptoms, advance care planning Fluid, anemia, renal bone disease management same for CCC and RRT groups	Mortality Time = 0 at eGFR <20 < 15 < 12	N = 172 Age not reported	N = 269 Age not reported Modes not reported	+Age +Comorbidity – Performance status + Institutionalized
Seow, 2013 (39)	Singapore Single center	Prospective cohort Age >75 or comorbid (Charlson score ≥8) And eGFR 8–12 Serial quality of life measurements 2007–9		Quality of life	N = 63 Median 78	N = 38 Median 71	+Age (Karnofsky and Charlson comorbidity index same)

Table 2. (Continued)

Study	Setting	Design	Conservative care intervention	Primary outcome	Sample characteristics		Baseline comparison CCC vs. RRT
					CCC	Dialysis	
Shum, 2014 (45)	Hong Kong China Single center	Retrospective cohort Age $\geq 65$ eGFR $< 15$ receiving pre-dialysis assessment 2003–10	Regular clinic follow-up same medical care as RRT	Mortality Time = 0 at eGFR $< 15$	N = 42 Mean 75	N = 157 Mean 73 PD	+Age +No helper for PD +Stroke +Social assistance
Brown, 2015 (29)	Australia Single center	Prospective cohort Recruited when attended predialysis clinic or renal supportive care clinic Dialysis group included separate late referrals 2009–13	Renal supportive care clinic in addition to usual nephrology care. Address symptoms and advance care planning.	Mortality Time = 0 at time of decision-making	N = 122 Mean age 82 Two patients planning for CCT started dialysis	N = 273 Mean age 67 33 patients planning for RRT started CCC and 72 started a dialysis modality different from planned HD & PD	+Age +Comorbidity +Malnutrition -SF36 PCS +Symptoms
Verberne, 2016 (46)	Netherlands Single center 2004–14	Retrospective cohort Age $\geq 70$ eGFR $< 20$	Full medical and multidisciplinary care	Mortality Time = 0 at time of mode choice	N = 107 Mean age 83 Two patients switched to RRT	N = 204 Mean age 76 HD & PD 12 patients switched to CCC	+Age No difference in comorbidity +eGFR at Decision

TABLE 3. Outcomes in studies comparing comprehensive conservative care (CCC) and dialysis

Study	Univariate survival CCC vs. dialysis	Adjusted survival	Hospitalization	Quality of life	Other outcomes
Joly, 2003 (42)	Median survival 8.9 months vs. 28.9 months $p < 0.001$ 1 year survival 29% vs. 74%				
Smith, 2003 (41)	Survival significantly worse for CCC group Survived slightly longer (2 months) if switched from CCC to dialysis vs. continuing CCC	Cox proportional hazard not significant for CCC intended and then dialyzed vs. CCC intended and not dialyzed			More deaths in CCC group were at home or in a hospice ( $p < 0.001$ )
Murtagh, 2007 (44)	Median time to death or study end 540 days vs. 588 days $p < 0.001$ 1 year survival 68% vs. 84%	No difference in survival if comorbidity grade 2 especially if had ischemic heart disease Significant predictors: CCC vs. dialysis Ischemic heart disease			
Carson, 2009 (48)	Median survival 13.9 vs. 37.8 months $p < 0.01$	None	Hospital days 16 CCC vs. 25 hemodialysis per patient year		Place of death at home odds ratio for CCC 4.15 (1.67–10.25)
Teo, 2010 (47)	1 year survival 69% vs. 22% peritoneal dialysis and 20% hemodialysis	Cox proportional hazard CCC HR 2.29 (1.16–4.45) adjusted age sex, race, LV ejection fraction, therapy center	Mean number of admissions 2.63 CCC vs. 3.45 hemodialysis vs. 3.2 peritoneal dialysis (not significant)		
Chandna, 2011 (40)	Median survival in those age >75 and low comorbidity 29.4 vs. 36.8 ( $p = 0.03$ ) High comorbidity 20.4 vs. 25.8 months (not significant)	Cox proportional hazard model in age >75 RRT pathway survive 4 months longer (not significant) Adjusted for age, gender comorbidity, diabetes			
Da Silva- Gane, 2012 (38)	Median survival 913 vs. 1317 days (vs. HD only)	Adjusted hazard ratio for hemodialysis vs. CCC 0.47 (0.2–1.1) $p = 0.08$ Adjusted for comorbidity, performance status, age, physical health component of SF-36 and propensity score		Quality of life summary over time: No differences over time in quality of life assessments, depression or anxiety Life satisfaction fell at dialysis initiation below levels in CCC group, which were stable	

Table 3. (Continued)

Study	Univariate survival CCC vs. dialysis	Adjusted survival	Hospitalization	Quality of life	Other outcomes
Hussain, 2013 (43)	Survival at 1 year 58% vs. 72% Survival on RRT greater from time of eGFR 20,15 or 12	RRT survival advantage became non-significant in older age (>80) or WHO Performance score >3, and much reduced if more comorbid	RRT group at increased risk of hospitalization relative risk 1.6 (1.1–2.1) $p < 0.05$		76% CCC accessed community palliative care, 0% RRT CCC group had greater chance of death outside hospital (though high levels of missing data)
Seow, 2013 (39)				No difference in CCC or RRT quality of life trajectories (Kidney disease specific Short form 36) after adjustment, except RRT initiation showed benefit to cognitive function score and adverse impact on burden of kidney disease and effects of kidney disease scores	
Shum, 2014 (45)	Median survival 2.35 vs. 3.79 years $p < 0.001$	Cox proportional hazard ratio for PD 0.46 (0.31–0.68) adjusted for age, comorbidities and impairment in activities of daily living Advantage lost in high comorbidity or if impaired daily living	Greater hospital days and emergency hospitalization in CCC even after adjustment for age, comorbidity and functional status		Less bothersome intervention at end of life and more renal palliative care $p < 0.001$ No difference in institutionalization
Brown, 2015 (29)	Mean 20 vs. 33 months Cause of Death was more commonly renal failure in CCC than RRT group	Various sub-group analyses If age >75 with $\geq 2$ comorbidities including coronary disease or heart failure, hazard ratio for RRT 0.48 (0.21–1.09) [small numbers]		Symptoms and quality of life, where reported often stable or improved with no difference between CCC and dialysis	
Verberne, 2016 (46)	Median survival 1.5 vs. 3.1 years Less difference in age >80, age <70 with Davies comorbidity score >3 or if cardiovascular disease	Age, comorbidity and mode significant Hazard ratio for RRT vs. CCC 0.60 (0.42–0.92)			

hospitalization rates and longer time spent in hospital compared with those receiving CCC (43,47,48), except in one study of patients receiving peritoneal dialysis, where the reverse was found (45). In the three studies that examined changes in quality of life (29,38,39), there were some baseline differences with lower scores in

patients on a nondialysis pathway, notably in terms of their physical health. However, quality of life was more stable over time in those receiving nondialysis care in contrast to those who started dialysis, where an adverse impact on burden of disease and life satisfaction was seen, with no apparent quality of life gained.

### Attitudes of Medical Staff, Patients, and their Families to CCC

Given the lack of high-quality comparative outcome data to guide decision-making, it is crucial to understand how clinicians and patients view management options. Different patients may view the same treatment in different ways and it is important for clinicians to understand individual patients' needs and how these may influence decisions. Qualitative research, aimed at exploring people's views of various life experiences, can help to unearth the beliefs and expectations people hold regarding their health, quality of life, and medical treatments.

A significant proportion of the qualitative literature has explored patients' perceptions of choosing between types of ESKF treatment, most frequently between dialysis modalities, and living with dialysis. Qualitative syntheses of this type of work have highlighted that patients consider various aspects when deciding what type of treatment is right for them (49,50). Patients are seen to consider the effect of treatment on their lifestyle and the impact on family members. They can experience great uncertainty when making treatment choices as they are unclear how their CKD is likely to progress and unsure about what different treatment approaches can offer.

More recently, researchers have started to explore patients' views of nondialysis care. Five studies have explored older patients' reasons for choosing nondialysis care (28,36,51–53). These indicate that the perceived burden of dialysis is a common reason why patients may choose nondialysis care. Patients report that their age and functional ability make attending dialysis sessions demanding and, as a consequence, feel dialysis would negatively affect their quality of life (51–53). Many older adults report difficulties in attending dialysis either because of availability of transport, time taken, or cost of travel (51). Patients also feel that choosing dialysis may be a burden on family members; interrupting their lives or causing them emotional stress (28). Such practicalities can outweigh perceived benefit of dialysis and those who feel they have lived a fulfilled life may not want treatment that disrupts their way of living (28,36,53).

When choosing nondialysis care patients most often report feeling that they have made an informed and autonomous decision (28,36). Patients report having opportunities to discuss their options with clinical staff and feel equipped to make decisions (52). However, patients state that information about dialysis is often given priority by staff and that nondialysis care may be discussed little or not at all (53). Decision aids and information leaflets are likely to be heavily weighted toward dialysis options, possibly reflecting the amount of evidence in this area.

Interviews with individuals indicate that patients may hold misunderstandings about CKD as a disease and what treatment can offer. Most often

patients are uncertain about how their disease will progress and what this will mean for the future. Some patients opting for nondialysis care report feeling well, reporting no symptoms from their CKD and as a result do not see the need for dialysis (52,53). Patients can fail to recognize how their CKD may progress and make treatment decisions based on how they feel in the present rather than on how they might feel in the future (51). This could explain why some patients change their minds and request dialysis once symptoms develop (53).

A small number of studies have explored clinicians' views on how treatment decisions are made with patients (20,54,55). Interviews with health professionals have highlighted the difficulty nephrology staff have in explaining CKD treatment and getting patients to appreciate the severity of the disease (20,54,55). Lack of public awareness of CKD and its treatment are perceived to contribute to this. Clinicians report additional challenges such as tailoring information to the educational level of the patient, eliciting patient concerns about treatment options and discussing options with patients who fear dialysis after hearing the experiences of others (54). Clinicians often report the importance of timing discussions so patients not only have enough time to understand the information, but also introducing new material to patients gradually to avoid anxiety (55).

Clinicians report that uncertainty about disease progression makes it hard to advise patients on management options and to prepare them for future treatment (20,55). Uncertainty can lead to clinicians avoiding discussions about the future; fearing that information will be too negative for patients (55). Discussions about prognosis or end of life may be delayed until prompted by the patient or by illness progression.

Only one study to date has specifically sought clinicians' views on nondialysis care (20). Clinicians generally accepted it as an alternative to dialysis, with most being grateful that they could offer something to patients if they did not choose dialysis. Clinicians reported that discussing nondialysis options with patients was a difficult task, more suited to experienced professionals because of the complexity and sensitivity of end of life issues. Clinicians felt more able to have these discussions when they felt confident in talking about end of life and in eliciting patient expectations. Such open discussions were felt to prevent misunderstandings and patients changing their mind between treatment options when symptoms developed at a later stage (20). Similar qualitative work with clinicians focusing on advanced care planning for patients with CKD has also identified that staff may not view such discussions as part of their role and that clinical teams may not have a shared understanding of advanced care planning (56). Research with patients indicates that timely information regarding ACP can help to support patient's psychological needs when undergoing treatment for ESKF (57).

TABLE 4. Pharmacological treatment of patients on the nondialysis pathway

Goal	Rationale	Approach	Risks/Burdens	Nondialysis preparation	CCC	Approaching end of life
Symptom control	<ul style="list-style-type: none"> <li>Manage</li> <li>Pruritus</li> <li>Lethargy</li> <li>Insomnia</li> <li>Restless legs</li> <li>Anorexia</li> <li>Nausea/vomiting</li> <li>Pain</li> <li>Depression</li> </ul>	<ul style="list-style-type: none"> <li>Non-pharmacological</li> <li>Pharmacological</li> <li>See KDIGO report (18)</li> </ul>	<ul style="list-style-type: none"> <li>Polypharmacy</li> <li>Sedation</li> <li>Constipation</li> <li>Other side effects</li> </ul>	Symptomatic benefit likely <b>Treatment recommended, regular symptom screening using validated tools and stepwise approach(18)</b>	Symptomatic benefit likely <b>Treatment recommended, regular symptom screening using validated tools and stepwise approach(18)</b>	Symptomatic benefit likely <b>Treatment recommended, regular symptom screening using validated tools and stepwise approach(18)</b>
Preservation of residual renal function	<ul style="list-style-type: none"> <li>Delay/prevent ESKF</li> <li>Prolong ESKF-free life</li> <li>Prolong life</li> </ul>	<ul style="list-style-type: none"> <li>ACE inhibitors/Angiotensin 2 receptor blockers</li> <li>Blood pressure control</li> <li>Treating primary disease (e.g. glycaemic control)</li> <li>ACE inhibitor/Angiotensin 2 receptor blocker withdrawal at low eGFR</li> </ul>	<ul style="list-style-type: none"> <li>Polypharmacy</li> <li>Hyperkalaemia and acute kidney injury with ACE inhibitors/Angiotensin 2 receptor blockers</li> <li>Postural hypotension and falls</li> <li>ACE inhibitor/Angiotensin 2 receptor blocker withdrawal may accelerate disease progression</li> </ul>	May delay/prevent ESKF and prolong life Symptomatic benefit unlikely <b>Treatment recommended</b>	Prevention of ESKF no longer possible. Risks of treatment heightened. Symptomatic benefit unlikely Competing risk of death high <b>Individualized approach needed</b>	Prevention of ESKF or life prolongation no longer beneficial Symptomatic benefit unlikely <b>Treatment not recommended</b>
Prevent cardiovascular complications (Primary & Secondary prevention)	<ul style="list-style-type: none"> <li>Prolong life</li> <li>Prevent disabling comorbidity</li> <li>Reduce hospital admission</li> </ul>	<ul style="list-style-type: none"> <li>ACE inhibitors</li> <li>Blood pressure control</li> <li>Statins</li> <li>Glycaemic control</li> <li>Smoking cessation</li> </ul>	<ul style="list-style-type: none"> <li>Polypharmacy</li> <li>Hyperkalaemia and acute kidney injury with ACE inhibitors/Angiotensin 2 receptor blockers</li> <li>Postural hypotension and falls</li> </ul>	May prolong life and prevent comorbidity Symptomatic benefit unlikely <b>Treatment recommended</b>	May prolong life and prevent comorbidity Symptomatic benefit unlikely Competing risk of death high <b>Individualized approach needed</b>	Meaningful benefit unlikely Symptomatic benefit unlikely <b>Treatment not recommended</b>
Treat renal bone disease	<ul style="list-style-type: none"> <li>Prevent fractures</li> <li>Prevent bone pain</li> </ul>	<ul style="list-style-type: none"> <li>Dietary phosphate restriction</li> <li>Phosphate binders</li> <li>Vitamin D</li> <li>Parathyroidectomy</li> <li>Calcimimetics</li> </ul>	<ul style="list-style-type: none"> <li>Polypharmacy</li> <li>Tablet burden</li> <li>Hypercalcaemia</li> <li>Hypocalcaemia</li> <li>Unpleasant diet</li> </ul>	May prevent future fractures Symptomatic benefit unlikely <b>Treatment recommended</b>	Prevention of future fractures possible Symptomatic benefit unlikely Competing risk of death high <b>Individualized approach needed</b>	Unlikely to reduce fractures Symptomatic benefit unlikely <b>Treatment not recommended</b>

**Table 4.** (Continued)

Goal	Rationale	Approach	Risks/Burdens	Nondialysis preparation	CCC	Approaching end of life
Manage fluid retention	<ul style="list-style-type: none"> <li>Prevent swelling and breathlessness</li> <li>Treat congestive cardiac failure</li> <li>Reduce chance of acute pulmonary edema</li> <li>Reduce hospital admission</li> </ul>	<ul style="list-style-type: none"> <li>Dietary salt restriction</li> <li>Dietary fluid restriction</li> <li>Diuretics</li> </ul>	<ul style="list-style-type: none"> <li>Polypharmacy</li> <li>Worsening renal function</li> <li>Gout</li> <li>Electrolyte disturbance</li> <li>Risk of acute kidney injury</li> <li>Unpleasant diet</li> </ul>	<p>Symptomatic benefit likely</p> <p><b>Treatment recommended, adjusted to clinical response and laboratory results</b></p>	<p>Symptomatic benefit likely</p> <p><b>Treatment recommended, adjusted to clinical response and laboratory results</b></p>	<p>Symptomatic benefit likely</p> <p><b>Treatment recommended, adjusted to clinical response</b></p> <p><b>Consider stopping blood tests</b></p> <p><b>Lifting dietary restrictions may improve quality of life</b></p>
Manage anemia	<ul style="list-style-type: none"> <li>Prevent breathlessness</li> <li>Reduce fatigue</li> <li>Reduce transfusion</li> <li>Prevent cardiac failure</li> </ul>	<ul style="list-style-type: none"> <li>Reduce transfusion</li> <li>Iron therapy</li> <li>Reduce transfusion</li> <li>Erythropoiesis stimulating agents</li> <li>Transfusion</li> </ul>	<ul style="list-style-type: none"> <li>Stroke</li> <li>Hypertension</li> <li>Transfusion reaction</li> <li>Anaphylaxis</li> </ul>	<p>Symptomatic benefit likely</p> <p><b>Treatment recommended as per guidelines</b></p>	<p>Symptomatic benefit likely</p> <p><b>Treatment recommended—individualized Hb targets may be appropriate</b></p>	<p>Symptomatic benefit possible</p> <p><b>Treatment recommended</b></p> <p><b>Transfusion may be required for rapid effect</b></p>
Prevent hyperkalaemia	<ul style="list-style-type: none"> <li>Reduce risk of sudden cardiac death</li> </ul>	<ul style="list-style-type: none"> <li>Dietary potassium restriction</li> <li>Diuretics</li> <li>Stopping ACE inhibitors/angiotensin 2 receptor blockers</li> <li>Exchange resins</li> </ul>	<ul style="list-style-type: none"> <li>Polypharmacy</li> <li>Unpleasant diet</li> <li>Electrolyte disturbance</li> </ul>	<p>May prolong life</p> <p>Symptomatic benefit unlikely</p> <p><b>Treatment recommended</b></p>	<p>May prolong life</p> <p>Symptomatic benefit unlikely</p> <p><b>Treatment recommended</b></p> <p><b>Consider stopping blood tests</b></p> <p><b>Lifting dietary restrictions may improve quality of life</b></p>	<p>May prolong dying</p> <p>Symptomatic benefit unlikely</p> <p><b>Treatment not recommended</b></p> <p><b>Consider stopping blood tests</b></p> <p><b>Lifting dietary restrictions may improve quality of life</b></p>

ACE, angiotensin converting enzyme; eGFR estimated glomerular filtration rate; ESKF, end-stage kidney failure; Hb, hemoglobin. Text in bold represents specific treatment recommendations based on likelihood of treatment benefit or burden.

## Components of Nondialysis Care

Patients who choose the nondialysis pathway are generally pursuing a less disruptive approach to their care (49). Balancing minimal therapeutic burden with maximal symptom control requires an enhanced focus on individualized goals, preferences, and values. Ascertainment of these must be a routine component of planning treatment. Clinicians who can elicit expectations can correct misconceptions and help individuals understand how treatment options might impact upon their quality and quantity of life. Practicalities of treatment need to be considered alongside clinical benefits in order for patients to frame decisions in relation to their own lives. The organization of available nondialysis care is varied (19,20,56) and there is no evidence available to identify best practice. Systems that encourage continuity of care and guidance from multidisciplinary teams trained and experienced in communication skills, shared decision-making, end of life discussions, and advance care planning may be best. Integration with primary and palliative care services is needed.

The components of CCC are summarized in Table 1 (18). However, all individuals with advanced CKD need these components addressed and ultimately it is preparation for and delivery of RRT which delineates the care pathways. Given the evolving nature of disease and personal preferences, regular review is needed to ensure treatment is aligned with achievable goals. For some, this will involve movement between the care pathways (Fig. 2). Many individuals will wish to concentrate on quality of life over longevity. Others may value life extension more highly and this stance is not discordant with nondialysis care for those with a poor prognosis. Potential therapeutic benefits are offset by treatment burdens, side effects, and the competing risk of death.

The majority of patients in a nondialysis preparation phase will receive treatment undifferentiated from routine CKD care. Those approaching end of life and those who develop ESKF may choose to reduce or stop treatment such as antihypertensives that offer no immediate symptomatic benefit and a low probability of life prolongation. Others will decide to continue such treatment if they feel the benefits outweigh the burdens. High quality shared decision-making is needed to facilitate informed choices. Treatment for patients on the nondialysis pathway is summarized in Table 4.

## The Future of Nondialysis Care—Conclusion and Recommendations

Given the human and economic impact of dialysis, there is a pressing need to establish the comparative effectiveness and cost-effectiveness of RRT and nondialysis care. It is incumbent on the nephrology community to generate the best possible evidence of person-centered health outcomes associated with each treatment approach and learn how

to present this evidence to patients in a way that allows them to make decisions that are most appropriate for them. The following five recommendations are focussed on this aim.

1. Agreed definitions are required that clearly distinguish phases of treatment. A suggested framework is proposed (Fig. 2).
2. Nondialysis care should be discussed early and openly with patients approaching ESKF and should feature more prominently in decision-support materials.
3. Improved observational and organizational research is needed to gain a better understanding of the natural history of advanced CKD and ESKF and to identify the most effective and efficient ways to deliver care and monitor equity of care. This could be achieved through a combination of extending RRT registries to capture earlier stages of CKD and by studying routine hospital and primary care databases. Improved capture of early dialysis outcomes and inclusion of patients with CKD including those on CCC (58) will improve data capture in areas known to be deficient (Fig. 1). Auditable standards and quality assurance data could help to coordinate more consistent care at a national level, and ensure equity of delivery.
4. The viability of a trial comparing the effectiveness and cost-effectiveness of nondialysis and RRT care pathways in individuals where clinical equipoise exists should be investigated. While practical and ethical intricacies make this challenging, observational data may never be able to separate unmeasured confounding by indication from treatment effect.
5. Working with colleagues in primary care and palliative medicine, the renal community must continue to strive to improve dialysis outcomes for older patients and those with multiple comorbidities, including greater use of home and assisted therapies. The benefits and risks of RRT are not fixed and whatever evidence is generated regarding nondialysis pathways will need to keep pace with advances in practice.

## References

1. Blagg CR: The early history of dialysis for chronic renal failure in the United States: a view from Seattle. *Am J Kidney Dis* 49(3):482–496, 2007
2. Lee CP, Chertow GM, Zenios SA: An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. *Value Health* 12(1):80–87, 2009
3. Caskey FJ, Kramer A, Elliott RF, Stel VS, Covic A, Cusumano A, et al.: Global variation in renal replacement therapy for end-stage renal disease. *Nephrol Dial Transplant* 26(8):2604–2610, 2011
4. Steenkamp R, Rao A, Fraser S: UK Renal Registry 18th Annual Report (December 2015) Chapter 5: survival and causes of death in UK adult patients on renal replacement therapy in 2014: National and centre-specific analyses. *Nephron* 132 Suppl 1:111–144, 2016
5. United States Renal Data System 2015 Annual Data Report: epidemiology of kidney disease in the United States. Chapter 13: International Comparisons. *Am J Kidney Dis* 67(3):S291–S334, 2016

6. Steenkamp R, Caskey F: UK Renal Registry 18th Annual Report: chapter 6 comorbidities and current smoking status amongst patients starting renal replacement therapy in England, Wales and Northern Ireland from 2013 to 2014. *Nephron* 132 Suppl 1:145–154, 2016
7. Office for National Statistics. National Population Projections, 2010-Based Projections 2011. Available at <http://www.ons.gov.uk/people-populationandcommunity/populationandmigration/populationprojections/bulletins/nationalpopulationprojections/2011-10-26> accessed August 6, 2016.
8. Ariès P: *Western attitudes towards death from the middle ages to the present*. Baltimore, MD: Johns Hopkins University Press, 1974
9. Recent Trends in Place of Death in England. Available at [http://www.endoflifecare-intelligence.org.uk/data\\_sources/place\\_of\\_death](http://www.endoflifecare-intelligence.org.uk/data_sources/place_of_death), accessed August 6, 2016.
10. Angus DC, Barnato AE, Linde-Zwirble WT, Weissfeld LA, Watson RS, Rickert T, et al.: Use of intensive care at the end of life in the United States: an epidemiologic study. *Crit Care Med* 32(3):638–643, 2004
11. Barber ND, Alldred DP, Raynor DK, Dickinson R, Garfield S, Jesson B, et al.: Care homes' use of medicines study: prevalence, causes and potential harm of medication errors in care homes for older people. *Qual Saf Health Care* 18(5):341–346, 2009
12. Spatz ES, Krumholz HM, Moulton BW: The new era of informed consent: getting to a reasonable-patient standard through shared decision making. *JAMA* 315(19):2063–2064, 2016
13. Shippee ND, Shah ND, May CR, Mair FS, Montori VM: Cumulative complexity: a functional, patient-centered model of patient complexity can improve research and practice. *J Clin Epidemiol* 65(10):1041–1051, 2012
14. May C, Montori VM, Mair FS: We need minimally disruptive medicine. *BMJ* 339:b2803, 2009
15. Kumwenda M, Mitra S, Reid C: The Renal Association guideline: Vascular Access for Haemodialysis 2015. Available at <http://www.renal.org/guidelines/modules/vascular-access-for-haemodialysis>, accessed 02 06, 2016
16. Warwick G, Mooney A, Russon L, Hardy R; The Renal association guideline: Planning, Initiating and Withdrawal of Renal Replacement Therapy 2014. Available at <http://www.renal.org/guidelines/modules/planning-initiating-and-withdrawal-of-renal-replacement-therapy>, accessed 02 06, 2016
17. Galla JH: Clinical practice guideline on shared decision-making in the appropriate initiation of and withdrawal from dialysis. The Renal Physicians Association and the American Society of Nephrology. *J Am Soc Nephrol* 11(7):1340–1342, 2000
18. Davison SN, Levin A, Moss AH, Jha V, Brown EA, Brennan F, et al.: Executive summary of the KDIGO Controversies Conference on supportive care in chronic kidney disease: developing a roadmap to improving quality care. *Kidney Int* 88(3):447–459, 2015
19. Parvez S, Abdel-Kader K, Pankratz VS, Song MK, Unruh M: Provider knowledge, attitudes, and practices surrounding conservative management for patients with advanced CKD. *Clin J Am Soc Nephrol* 11(5):812–820, 2016
20. Roderick P, Rayner H, Tonkin-Crine S, Okamoto I, Eyles C, Leydon G, et al.: A national study of practice patterns in UK renal units in the use of dialysis and conservative kidney management to treat people aged 75 years and over with chronic kidney failure. *Health Serv Deliv Res* 3(12):1–186, 2015
21. Gilg J, Caskey F, Fogarty D: UK Renal Registry 18th Annual Report: Chapter 1 UK Renal Replacement Therapy Incidence in 2014: National and Centre-specific Analyses. *Nephron* 132 Suppl 1:9–40, 2016
22. Goldacre MJ: Cause-specific mortality: understanding uncertain tips of the disease iceberg. *J Epidemiol Community Health* 47(6):491–496, 1993
23. Zoccali C, Kramer A, Jager KJ: Chronic kidney disease and end-stage renal disease—a review produced to contribute to the report 'the status of health in the European union: towards a healthier Europe'. *Clin Kidney J* 3(3):213–224, 2009
24. Pruthi R, Casula A, MacPhee I: UK Renal Registry 18th Annual Report: Chapter 3 Demographic and Biochemistry Profile of Kidney Transplant Recipients in the UK in 2014: National and Centre-specific Analyses. *Nephron* 132 Suppl 1:69–98, 2016
25. Caskey FJ, Schober-Halstenberg HJ, Roderick PJ, Edenharter G, Ansell D, Frei U, et al.: Exploring the differences in epidemiology of treated ESRD between Germany and England and Wales. *Am J Kidney Dis* 47(3):445–454, 2006
26. Liu FX, Rutherford P, Smoyer-Tomic K, Prichard S, Laplante S: A global overview of renal registries: a systematic review. *BMC Nephrol* 16:31, 2015
27. Van De Luijngaarden MWM, Noordzij M, Van Biesen W, Couchoud C, Cancarini G, Bos WJW, et al.: Conservative care in Europe – Nephrologists' experience with the decision not to start renal replacement therapy. *Nephrol Dial Transplant* 28(10):2604–2612, 2013
28. Seah AS, Tan F, Srinivas S, Wu HY, Griva K: Opting out of dialysis – Exploring patients' decisions to forego dialysis in favour of conservative non-dialytic management for end-stage renal disease. *Health Expect* 18(5):1018–1029, 2015
29. Brown MA, Collett GK, Josland EA, Foote C, Li Q, Brennan FP: CKD in elderly patients managed without dialysis: survival, symptoms, and quality of life. *Clin J Am Soc Nephrol* 10(2):260–268, 2015
30. Department of Health: *National Service Framework for Renal Services: Part 2*. London: Department of Health, 2005
31. Agarwal R: Defining end-stage renal disease in clinical trials: a framework for adjudication. *Nephrol Dial Transplant* 31(6):864–867, 2016
32. Evans M, van Stralen KJ, Schon S, Prutz KG, Stendahl M, Rippe B, et al.: Glomerular filtration rate-estimating equations for patients with advanced chronic kidney disease. *Nephrol Dial Transplant* 28(10):2518–2526, 2013
33. Lameire N, Van Biesen W: The initiation of renal-replacement therapy—just-in-time delivery. *N Engl J Med* 363(7):678–680, 2010
34. Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB, et al.: A randomized, controlled trial of early versus late initiation of dialysis. *N Engl J Med* 363(7):609–619, 2010
35. Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, et al.: The frequency of hyperkalemia and its significance in chronic kidney disease. *Arch Intern Med* 169(12):1156–1162, 2009
36. Noble H, Meyer J, Bridges J, Kelly D, Johnson B: Reasons renal patients give for deciding not to dialyze: a prospective qualitative interview study. *Dial Transplant* 38(3):82–89, 2009
37. Foote C, Morton RL, Jardine M, Gallagher M, Brown M, Howard K, et al.: Considerations of nephrologists when suggesting dialysis in elderly patients with renal failure (CONSIDER): a discrete choice experiment. *Nephrol Dial Transplant* 29(12):2302–2309, 2014
38. Da Silva-Gane M, Wellsted D, Greenshields H, Norton S, Chandna SM, Farrington K: Quality of life and survival in patients with advanced kidney failure managed conservatively or by dialysis. *Clin J Am Soc Nephrol* 7(12):2002–2009, 2012
39. Seow YY, Cheung YB, Qu LM, Yee AC: Trajectory of quality of life for poor prognosis stage 5D chronic kidney disease with and without dialysis. *Am J Nephrol* 37(3):231–238, 2013
40. Chandna SM, Da Silva-Gane M, Marshall C, Warwicker P, Greenwood RN, Farrington K: Survival of elderly patients with stage 5 CKD: comparison of conservative management and renal replacement therapy. *Nephrol Dial Transplant* 26(5):1608–1614, 2011
41. Smith C, Da Silva-Gane M, Chandna S, Warwicker P, Greenwood R, Farrington K: Choosing not to dialyze: evaluation of planned non-dialytic management in a cohort of patients with end-stage renal failure. *Nephron Clin Pract* 95(2):c40–c46, 2003
42. Joly D, Anglicheau D, Alberti C, Nguyen AT, Touam M, Grunfeld JP, et al.: Octogenarians reaching end-stage renal disease: cohort study of decision-making and clinical outcomes. *J Am Soc Nephrol* 14(4):1012–1021, 2003
43. Hussain JA, Mooney A, Russon L: Comparison of survival analysis and palliative care involvement in patients aged over 70 years choosing conservative management or renal replacement therapy in advanced chronic kidney disease. *Palliat Med* 27(9):829–839, 2013
44. Murtagh FE, Marsh JE, Donohoe P, Ekbal NJ, Sheerin NS, Harris FE: Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5. *Nephrol Dial Transplant* 22(7):1955–1962, 2007
45. Shum CK, Tam KF, Chak WL, Chan TC, Mak YF, Chau KF: Outcomes in older adults with stage 5 chronic kidney disease: comparison of peritoneal dialysis and conservative management. *J Gerontol A Biol Sci Med Sci* 69(3):308–314, 2014
46. Verberne WR, Geers AB, Jellema WT, Vincent HH, van Delden JJ, Bos WJ: Comparative survival among older adults with advanced kidney disease managed conservatively versus with dialysis. *Clin J Am Soc Nephrol* 11(4):633–640, 2016
47. Teo BW, Ma V, Xu H, Li J, Lee EJ; Nephrology Clinical Research G: Profile of hospitalisation and death in the first year after diagnosis of end-stage renal disease in a multi-ethnic Asian population. *Ann Acad Med Singapore* 39(2):79–87, 2010
48. Carson RC, Juszczak M, Davenport A, Burns A: Is maximum conservative management an equivalent treatment option to dialysis for elderly patients with significant comorbid disease? *Clin J Am Soc Nephrol* 4(10):1611–1619, 2009
49. Morton RL, Tong A, Howard K, Snelling P, Webster AC: The views of patients and carers in treatment decision making for chronic kidney disease: systematic review and thematic synthesis of qualitative studies. *BMJ* 340:c112, 2010
50. Harwood L, Clark AM: Understanding pre-dialysis modality decision-making: a meta-synthesis of qualitative studies. *Int J Nurs Stud* 50(1):109–120, 2013
51. Visser A, Dijkstra GJ, Kuiper D, de Jong PE, Franssen CFM, Gansevoort RT, et al.: Accepting or declining dialysis: considerations taken into account by elderly patients with end-stage renal disease. *J Nephrol* 22(6):794–799, 2009
52. Johnston S, Noble H: Factors influencing patients with stage 5 chronic kidney disease to opt for conservative management: a practitioner research study. *J Clin Nurs* 21(9–10):1215–1222, 2012
53. Tonkin-Crine S, Okamoto I, Leydon GM, Murtagh FEM, Farrington K, Caskey F, et al.: Understanding by older patients of dialysis and

- conservative management for chronic kidney failure. *Am J Kidney Dis* 65(3):443–450, 2015
54. Greer RC, Ameling JM, Cavanaugh KL, Jaar BG, Grubbs V, Andrews CE, et al.: Specialist and primary care physicians' views on barriers to adequate preparation of patients for renal replacement therapy: a qualitative study. *BMC Nephrol* 16:37, 2015
  55. Schell JO, Patel UD, Steinhauser KE, Ammarell N, Tulsy JA: Discussions of the kidney disease trajectory by elderly patients and nephrologists: a qualitative study. *Am J Kidney Dis* 59(4):495–503, 2012
  56. O'Hare AM, Szarka J, McFarland LV, Taylor JS, Sudore RL, Trivedi R, et al.: Provider perspectives on advance care planning for patients with kidney disease: whose job is it anyway? *Clin J Am Soc Nephrol* 11(5):855–866, 2016
  57. Davison SN, Simpson C: Hope and advance care planning in patients with end stage renal disease: qualitative interview study. *BMJ* 333(7574):886, 2006
  58. Caskey F, Cullen R: UK Renal Registry 18th Annual Report 2015. Introduction. *Nephron* 132(Suppl 1):1–7, 2016